Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Spatz

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenibJean Philippe Arnault, Janine Wechsler, Bernard Escudier, et al.
Molecular Oncology|April 23, 2009
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomasCaroline Kannengiesser, Alain Spatz, Stefan Michiels, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanomaBruce Elliott, Richard A Scolyer, Stefan Suciu, et al.
Journal of the National Cancer Institute|June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferonMarna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Journal of the National Cancer Institute|April 6, 2006
Gene expression profiling of primary cutaneous melanoma and clinical outcomeVéronique Winnepenninckx, Vladimir Lazar, Stefan Michiels, et al.
International Journal of Cancer|September 19, 2008
Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular responseLydie Cassard, Joel F G Cohen-Solal, Emilie M Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenibJean Philippe Arnault, Janine Wechsler, Bernard Escudier, et al.
Molecular Oncology|April 23, 2009
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomasCaroline Kannengiesser, Alain Spatz, Stefan Michiels, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanomaBruce Elliott, Richard A Scolyer, Stefan Suciu, et al.
Journal of the National Cancer Institute|June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferonMarna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Journal of the National Cancer Institute|April 6, 2006
Gene expression profiling of primary cutaneous melanoma and clinical outcomeVéronique Winnepenninckx, Vladimir Lazar, Stefan Michiels, et al.
International Journal of Cancer|September 19, 2008
Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular responseLydie Cassard, Joel F G Cohen-Solal, Emilie M Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Pageof 5